Autonomix Medical's Groundbreaking Patent Achievement
Autonomix Medical, Inc. (NASDAQ: AMIX), a pioneer in medical devices, has recently announced a remarkable achievement — the issuance of a U.S. patent for its innovative catheter-based technology focused on sensing data collection and processing. This patent not only reinforces the company's growing intellectual property portfolio but also highlights the technology's potential to transform the treatment of conditions related to the nervous system.
The Significance of the New Patent
The newly issued patent, officially numbered 12,217,863, is titled Medical Devices with Circuitry for Capturing and Processing Physiological Signals. This groundbreaking patent empowers Autonomix to safeguard its proprietary technology designed for real-time physiological monitoring. Its diverse applications range widely, including heart mapping, arterial mapping, parenchymal tracking, and central nervous system monitoring.
Brad Hauser, the CEO of Autonomix, expressed their enthusiasm regarding the patent's issuance. He emphasized that the ongoing positive data from their clinical efforts adds to their confidence in this pioneering technology, which addresses critical areas of unmet medical needs, especially in treating pain related to pancreatic cancer. The management team believes this innovation can significantly enhance patient care and improve treatment outcomes.
Revolutionary Technology for Enhanced Sensitivity
Autonomix's technology stands out due to its first-in-class catheter-based microchip sensing array. This innovative device may detect and differentiate neural signals with sensitivity much greater—up to 3,000 times better—than what's currently available. This heightened sensitivity facilitates precision in identifying target nerves. Once identified, Autonomix utilizes its proprietary radiofrequency (RF) ablation technology to precisely treat these nerves, offering a sophisticated approach to managing various health conditions ranging from chronic pain to hypertension.
Plans for Clinical Trials and Future Research
The company has ambitious plans to escalate its clinical research efforts. It intends to submit an Investigational Device Exemption (IDE) to the relevant U.S. regulatory authorities and anticipates commencing clinical trials in 2025. These trials aim to support the commercialization of the Autonomix Sensing and RF Ablation System as a therapeutic option for alleviating pain associated with pancreatic cancer.
The Vision of Autonomix Medical
Autonomix Medical holds a strong vision of reshaping the landscape of how diseases tied to the nervous system are diagnosed and treated. With its pioneering technology in the realm of pain management, particularly for conditions like pancreatic cancer, it aims to explore numerous other applications in fields such as cardiology and chronic pain management. This cutting-edge technology underscores the company's commitment to addressing pressing medical needs with innovative solutions.
Investor and Media Contact
For any inquiries, interested parties can reach out to the JTC Team, LLC. For specific questions, please contact Jenene Thomas at 908.824.0775 or via email at autonomix@jtcir.com.
Frequently Asked Questions
What is the patent number issued to Autonomix Medical?
The patent issued is numbered 12,217,863.
What technology does the patent cover?
The patent covers catheter-based technology for capturing and processing physiological signals.
How does Autonomix's technology improve treatment?
It uses a microchip sensing array allowing for significantly enhanced sensitivity in detecting neural signals.
When does Autonomix plan to start clinical trials?
Clinical trials are anticipated to commence in 2025.
What is the primary focus of Autonomix's technology?
The technology primarily aims to treat pain, particularly associated with pancreatic cancer.
